- Last participant enters human challenge trial, data expected by year end 2017
- New Supervisory Board members and investment
Gemuenden, Germany, 12 October, 2017 - Ventaleon GmbH, a biotechnology compan [...]
First non-dilutive funding received by ImCheck
following its initial fundraising of 20 M€ in May 2017
Marseille, France, 10 October 2017 – ImCheck Therapeutics, an emerging biopharmaceutical compa [...]
Non-regulated information
Breda, the Netherlands / Ghent, Belgium, September 25, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated [...]
Top-line data from the study expected in second half of 2018 -
Breda, the Netherlands / Ghent, Belgium, September 20, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company [...]
Amsterdam-Duivendrecht, The Netherlands, September 20, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developi [...]
UTRECHT, The Netherlands, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Merus (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing therapeutics with the goal of treating and curing serious illnesses, announced toda [...]
Omega and Fund+ broaden Immunic’s investor base and add an additional EUR 10 million (USD 12 million) in equity financing
Series A financing round now completed with an overall investment size of EUR 31.7 [...]
Schlieren (Zurich), Switzerland, August 28, 2017 – Kuros Biosciences announced today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for MagnetOs Putty indicated for use as an au [...]
- Last participant enters human challenge trial, data expected by year end 2017
- New Supervisory Board members and investment
Gemuenden, Germany, 12 October, 2017 - Ventaleon GmbH, a biotechnology compan [...]
First non-dilutive funding received by ImCheck
following its initial fundraising of 20 M€ in May 2017
Marseille, France, 10 October 2017 – ImCheck Therapeutics, an emerging biopharmaceutical compa [...]
Non-regulated information
Breda, the Netherlands / Ghent, Belgium, September 25, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated [...]
Top-line data from the study expected in second half of 2018 -
Breda, the Netherlands / Ghent, Belgium, September 20, 2017 - argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company [...]
Amsterdam-Duivendrecht, The Netherlands, September 20, 2017 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical stage biopharmaceutical company developi [...]
UTRECHT, The Netherlands, Sept. 20, 2017 (GLOBE NEWSWIRE) -- Merus (NASDAQ:MRUS), a clinical-stage immuno-oncology company developing therapeutics with the goal of treating and curing serious illnesses, announced toda [...]
Omega and Fund+ broaden Immunic’s investor base and add an additional EUR 10 million (USD 12 million) in equity financing
Series A financing round now completed with an overall investment size of EUR 31.7 [...]
Schlieren (Zurich), Switzerland, August 28, 2017 – Kuros Biosciences announced today that it has received 510(k) clearance from the US Food and Drug Administration (FDA) for MagnetOs Putty indicated for use as an au [...]
Follow us
